INmune Bio (NASDAQ:INMB) Stock Rating Upgraded by Wall Street Zen

INmune Bio (NASDAQ:INMB) was upgraded by analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a research note issued on Saturday.

INmune Bio Price Performance

INmune Bio stock opened at $1.29 on Friday. The stock has a market cap of $34.29 million, a PE ratio of -0.61 and a beta of 0.72. The stock’s fifty day moving average is $1.55 and its two-hundred day moving average is $1.79. INmune Bio has a 1-year low of $1.21 and a 1-year high of $11.64.

Institutional Trading of INmune Bio

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Quadrature Capital Ltd acquired a new position in shares of INmune Bio in the 4th quarter valued at $26,000. Intech Investment Management LLC purchased a new stake in INmune Bio in the second quarter valued at $26,000. Cary Street Partners Financial LLC acquired a new position in INmune Bio in the third quarter valued at $29,000. Independent Advisor Alliance purchased a new position in shares of INmune Bio during the third quarter worth about $30,000. Finally, Squarepoint Ops LLC acquired a new stake in shares of INmune Bio during the third quarter worth about $30,000. Institutional investors and hedge funds own 12.72% of the company’s stock.

INmune Bio Company Profile

INmune Bio, Inc is a clinical-stage immunology company based in San Diego, California, focused on harnessing the innate immune system to combat a range of serious diseases. The company’s research and development efforts concentrate on modulating cellular pathways to restore and enhance the body’s natural defenses, particularly in oncology and neurodegenerative conditions.

The company’s lead therapeutic candidate, XPro1595 (also referred to as INB03), is a proprietary selective inhibitor of soluble tumor necrosis factor (TNF) designed to reduce chronic inflammation without impairing membrane-bound TNF functions.